-
Mashup Score: 15
PURPOSE Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI) active in BCC that may radiosensitize BCC. We evaluated the combination of vismodegib and RT for patients with LA BCC. METHODS In this multicenter, single-arm, phase II study, patients with unresectable LA BCC received 12 weeks of induction vismodegib, followed by 7 weeks of concurrent vismodegib and RT. The primary end point was LRC rate at 1 year after the end of treatment. Secondary end points included objective response, progression-free survival (PFS), overall survival (OS), safety, and patient-reported quality of life (PRQOL). RESULTS Twenty-four patients received vismodegib; five were unable to complete 12 weeks of induction therapy. LRC was achieved in 91% (95% CI, 68 to 98) of patients at 1 year. The response rate was 63% (95% CI, 38 to 84) after induction vismo
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial - 2 month(s) ago
PURPOSE Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated inflammation. However, systemic side effects of celecoxib have limited routine prescription. Topical diclofenac inhibits COX-2 locally with minimal risk of systemic adverse events. Therefore, we conducted this study to assess the efficacy of topical diclofenac in the prevention of capecitabine-induced HFS. METHODS In this single-site phase III randomized double-blind trial, we enrolled patients with breast or GI cancer who were planned to receive capecitabine-based treatment. Participants were randomly assigned in a 1:1 ratio to receive topical diclofenac or placebo gel for 12 weeks or until the development of HFS, whichever occurred earlier. The primary end point was the incidence of grade 2 or 3 HFS (Common Terminology Criteria for Adverse Events version 5), which was compared between th
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial | Journal of Clinical Oncology https://t.co/5mw6qjCKyS @aiims_newdelhi @batraatulmd @atul1_p congratulations! @ASCO
-
-
Mashup Score: 2Checkpoint Inhibition for Kidney Transplant Recipients With Advanced Cutaneous Carcinomas: An Emerging Standard for Select Patients - 3 month(s) ago
Cutaneous squamous cell carcinoma (CSCC) is one of the most common cancers overall in the United States with over one million patients diagnosed annually. While most CSCCs are highly curable with surgery alone, 5%-10% of patients experience disease recurrence and death, which amounts to mortality rates exceeding those of melanoma. 1 One of the highest-risk populations with CSCC that experience poor outcomes is the immune suppressed population. First, immune-compromised patients are at up to a 250-fold
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Checkpoint Inhibition for Kidney Transplant Recipients With Advanced Cutaneous Carcinomas: An Emerging Standard for Select Patients | Journal of Clinical Oncology https://t.co/G8K2QsbRaD @ShlomoKoyfmanMD @JLGeigerMD @ASCO @ASDSmembers @AST_info
-
-
Mashup Score: 0Effect of distance of treatment center on survival for HPV-negative head and neck cancer patients - PubMed - 7 month(s) ago
For patients in this population-based cohort, those traveling greater distances for treatment of HPV-negative HNSCC had improved OS. This analysis suggests that the benefits of coordinated, multidisciplinary care may outweigh the barriers of travel burden for these patients.
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Effect of distance of treatment center on survival for HPV-negative head and neck cancer patients - PubMed #hnscm @ASTRO_org @ASCO @AHNSinfo https://t.co/z9QpmXJqNH
-
-
Mashup Score: 0
New 10-year follow-up data were published by Restrepo et al in Pediatrics on girls and boys who received a three-dose regimen of the 9-valent human papillomavirus (HPV) vaccine between the ages of 9 and 15. The long-term follow-up study was conducted from 2009 through 2021 across 13 countries and 5 continents. The phase III immunogenicity study for the 9-valent HPV vaccine in boys and girls aged 9 to 15 years was extended to a long-term follow-up study to assess immunogenicity through 10 years after the
Source: ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Efficacy of the 9-Valent HPV Vaccine 10-Year Follow-up - The ASCO Post @ASCO @ASTRO_org #hnscm #hpv @AHNSinfo https://t.co/kv4RJLQXLQ
-
-
Mashup Score: 1
March 31 2023Combined long-term survival results from nonrandomized phase II trial NRG Oncology RTOG 0630 and the ancillary analysis of the combined NRG-RTOG 0630/9514 trials indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma (STS) who receive preoperative chemoradiotherapy or radiotherapy. This data…
Source: NRGCategories: Hem/Oncs, Latest HeadlinesTweet-
Congratulations dianwang84 @RushCancer @RushMedical #sarcoma @NRGonc @JAMAOnc https://t.co/Z7FZt5bPVp
-
-
Mashup Score: 2
Outpatient care for cancer patients compromises 60 – 70% of healthcare costs over the last 6 months of life. Recent approvals for expensive biologics and growing support for lower-cost hypofractionated radiotherapy in the palliative management of advanced cancer have introduced offsetting spending effects on end-of-life care that may shift overall expenditures for this patient cohort.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Recent Trends in Medicare Payments for Outpatient Cancer Care at the End of Life - International Journal of Radiation Oncology, Biology, Physics https://t.co/2YNwRXZI6V
-
-
Mashup Score: 58
The world runs on trust. It is the oxygen of the healthcare system. It is easy to build hospitals and vaccines, but it is not easy to build trust. In my expe…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @jamecancerdoc: Building Trust is a Matter of Life and Death | Dr. Jame Abraham | TEDxMa... https://t.co/WK92QqvnvH via @YouTube - The w…
-
-
Mashup Score: 0Prognostic Value of Quantitative Neck Dissection Quality Measures in Patients With Clinically Node-Negative OCSCC - 2 year(s) ago
This cohort study examines the prognostic utility of lymph node yield and lymph node ratio in patients with clinically node-negative clinically localized oral cavity squamous cell carcinoma.
Source: jamanetwork.comCategories: Latest Headlines, Oncologists1Tweet-
Prognostic Value of Quantitative Neck Dissection Quality Measures in Patients With Clinically Node-Negative... https://t.co/uQlgH5BBNF via @JAMAOto part of @JAMANetwork
-
-
Mashup Score: 0
OBJECTIVE:. To assess trends in recent human papillomavirus (HPV) vaccination initiation and factors associated with vaccination among adolescents.METHODS:. The 2015 to 2020 National Immunization Survey–Teen data were used to assess vaccination trends. Multivariable logistic regression analysis were conducted to assess factors associated with vaccination.RESULTS:. Overall, HPV vaccination…
Source: American Academy of PediatricsCategories: Hem/Oncs, Latest HeadlinesTweet-
Human Papillomavirus Vaccination Trends Among Adolescents: 2015 to 2020 https://t.co/stBFtdgJWS #HPV #hnscm
-
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma | Journal of Clinical Oncology https://t.co/cpTADQ8sxO @sueyom